← back to search
Margaret M. Woo
Novartis (Switzerland) · CH
Area of research
Molecular Biology · Oncology
Research interest
Research interests include Panobinostat, Medicine, Neutropenia, Multiple myeloma, Internal medicine, and Tolerability.
h-index
—
citations
172
works
2
NIH funding
—
primary concept
—
email
✉ Find email ↗
Recent publications
Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies
Leukemia
2013
cited by
138
position: middle
doi
A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors
Investigational New Drugs
2013
cited by
34
position: middle
doi
Grants
No grants ingested yet.
Frequent collaborators
H. Miles Prince
· Melbourne Health
2
papers (2013–2013)
Jeffrey W. Scott
· Novartis (Switzerland)
1
papers (2013–2013)
Kapil N. Bhalla
· Cancer Clinic
1
papers (2013–2013)
Kathryn Parker
· University Health Network
1
papers (2013–2013)
Daniel J. DeAngelo
· Harvard University
1
papers (2013–2013)
Kaushal Mishra
· Novartis (Switzerland)
1
papers (2013–2013)
Sunil Sharma
· Translational Genomics Research Institute
1
papers (2013–2013)
Monica Mita
· Samueli Institute
1
papers (2013–2013)
—
·
1
papers (2013–2013)
Sofia Paul
· CellCentric (United Kingdom)
1
papers (2013–2013)
Andrew Spencer
· The Alfred Hospital
1
papers (2013–2013)
Thomas Kindler
· DC Cancer Consortium
1
papers (2013–2013)
—
·
1
papers (2013–2013)
Brian Gadbaw
· Novartis (Switzerland)
1
papers (2013–2013)
Peter Atadja
· Novartis (Switzerland)
1
papers (2013–2013)
Joachim Beck
· Johannes Gutenberg University Mainz
1
papers (2013–2013)
—
·
1
papers (2013–2013)
Anlan Liu
· Nanjing University of Chinese Medicine
1
papers (2013–2013)
Oliver G. Ottmann
· Cancer Genetics (United States)
1
papers (2013–2013)